Hanmi Pharmaceutical Control Dispute — Son vs. Mother-Daughter Alliance

Korea's pharmaceutical and bio industry began receiving global recognition for its R&D capabilities from the late 2010s, as successful technology licensing (license-out) cases accumulated. Hanmi Pharmaceutical led this trend. As of 2024, Korea's domestic pharmaceutical market is approximately KRW 30 trillion with rapidly expanding biopharma share. Korean firms are growing increasingly competitive in obesity drugs (GLP-1), oncology, and rare disease therapeutics. However, given the nature of drug development, leadership stability and long-term R&D investment continuity are core variables in pharmaceutical company valuation.

A control dispute in the pharmaceutical sector affects far more than shareholder composition — it cascades into long-term R&D strategy, technology licensing partnership maintenance, and global clinical trial continuity. Hanmi Pharmaceutical experienced a management vacuum while holding major pipelines across large-disease categories including obesity, diabetes, and anemia. This can weaken negotiation leverage with global pharma giants and delay long-term clinical investment decisions — a pharma-specific risk factor.

Hanmi Pharmaceutical is Korea's leading pharmaceutical company, founded by Sung-ki Lim in 1973. Its core business is the manufacture and sale of finished pharmaceuticals, with in-house drug development (R&D) capabilities rated best-in-class among Korean pharma companies. Key pipelines include Rolontis (efbemalenograstim alfa, sustained-release G-CSF for neutropenia), efpeglenatide (GLP-1 diabetes drug), and HM15211 (obesity drug), all in global clinical trials. Hanmi Science, as the holding company of Hanmi Pharmaceutical, is the actual battlefield of this control dispute — the side controlling the holding company's board exercises management authority over the operating company.

The Hanmi Pharmaceutical control dispute centers on a proxy fight over the composition of Hanmi Science's (holding company) board. In this dual structure where Hanmi Science controls Hanmi Pharmaceutical, the side that controls the holding company's board also governs the operating company. Both sides are engaged in proxy fights at every annual meeting to secure institutional and retail shareholder voting rights. As of 2024, with the dispute ongoing, the ownership structure has not been finally determined.

Given this is an intra-family control dispute, publicly available financial advisor information is limited. Both sides have been engaged primarily through legal counsel in proxy fights, director appointment injunctions, and will authenticity litigation. IR communication with institutional investors and proxy solicitation advisory have also played key roles.

Advisor information is based on public reporting. Significant details remain undisclosed given the private nature of an intra-family control dispute.

Unit: KRW 100 million (억원) | Hanmi Pharmaceutical consolidated estimates | Source: Public annual reports and IR materials

The financial core of the Hanmi Pharmaceutical control dispute is the holding company discount (Hanmi Science) and management risk premium. Hanmi Science trades at a significant discount to the global drug pipeline value of Hanmi Pharmaceutical, and the prolonged dispute is widening this discount. Some analysts value Hanmi Pharmaceutical's key pipelines (obesity, diabetes, anemia drugs) at several trillion won, but management uncertainty is limiting valuation recognition.

Valuation figures are estimated based on public reporting and IR materials. Actual figures may differ.

As of 2025, the Hanmi Pharmaceutical control dispute remains ongoing. Jong-yoon Lim partially returned to the Hanmi Science board in 2024 but has not achieved full board control. The Young-sook Song and Joo-hyun Lim faction maintains a board majority and continues OCI Group merger discussions. However, shareholder sentiment on the merger is divided, making final resolution elusive. Hanmi Pharmaceutical's key pipeline HM15211 (obesity drug) has shown visible progress in global clinical trials, intensifying concerns that prolonged management uncertainty will compound the erosion of corporate value.